Emily P Thi, Xin Ye, Nicholas M Snead, Amy C H Lee, Holly M Micolochick Steuer, Andrzej Ardzinski, Ingrid E Graves, Christine Espiritu, Andrea Cuconati, Cory Abbott, Agnes Jarosz, Xiaowei Teng, Bhavna Paratala, Kevin McClintock, Troy Harasym, Rene Rijnbrand, Angela M Lam, Michael J Sofia
Chronic hepatitis B is a global health concern with a high risk of end-stage liver disease. Current standard-of-care agents have low cure rates, and new therapies are needed. Small interfering RNAs (siRNAs) that target viral RNAs fulfill a gap not addressed by standard-of-care agents and may contribute to a functional cure. Here, we describe the preclinical characterization of imdusiran (AB-729), a novel, pan-genotypic siRNA therapeutic that effectively reduces HBsAg, viral antigens, and viral replication in chronic hepatitis B patients and is currently in Phase 2 clinical studies...
September 22, 2024: ACS Infectious Diseases